Last updated: August 2, 2025
Introduction
Denmark patent DK1849470, granted in 2007, pertains to a novel pharmaceutical composition or process associated with a specific therapeutic agent. As with any patent, understanding its scope, claims, and position within the patent landscape is vital for stakeholders—particularly in licensing, development, and competitive analyses. This report offers a comprehensive review of the patent's scope, claims, and the broader patent landscape in Denmark and globally, focusing on the implications for the pharmaceutical industry.
Scope and Claims of DK1849470
Patent Overview
DK1849470 covers innovative aspects in the field of drug delivery, formulation, or specific therapeutic compounds. It emphasizes novel use, formulation, or manufacturing processes designed to improve efficacy, stability, or bioavailability. The technical content, typically detailed in patent claims, defines the legal scope of the patent.
Claim Analysis
1. Independent Claims:
The independent claims primarily define the core innovation—likely centered on a unique composition, method of preparation, or therapeutic application. For example, an independent claim might specify a pharmaceutical composition comprising a specific active compound in a particular excipient matrix, with claims extending to its method of manufacture or use.
2. Dependent Claims:
Dependent claims refine the independent claims, introducing specific embodiments or variations (e.g., concentration ranges, specific excipients, delivery methods). They serve to protect narrower, optimized embodiments, thus broadening the patent’s proprietary coverage indirectly.
3. Scope of Claims:
The scope probably extends to specific chemical entities, their salts, esters, or derivatives, possibly within a defined chemical class. It may also cover formulations such as sustained-release tablets or injectable forms, including methods of administration.
Nature of Innovation
Based on typical patent strategies, the patent's novelty likely lies in:
- A novel chemical compound or a pharmacologically active derivative with improved therapeutic properties.
- A specific formulation or delivery system enhancing bioavailability or patient compliance.
- A unique manufacturing process producing the active compound more efficiently or with fewer impurities.
- A new therapeutic use or combination therapy involving the compound.
Legal Considerations and Validity
The scope must be carefully examined against prior art to confirm novelty and inventive step. The patent’s claims should be checked for breadth to evaluate potential infringement risks or licensing opportunities. DK1849470 likely underwent substantive examination to ensure compliance with Danish patent law, which aligns with European Patent Convention standards.
Patent Landscape
Global and European Patent Environment
Since Denmark is a member of the European Patent Organization, DK1849470's status influences and is influenced by the broader European patent landscape. Pharmaceutical patents in Europe benefit from centralized prosecution but must also consider national implementations.
Comparison with Similar Patents
- European Patent Applications: Similar inventions may be protected via European patent applications, potentially with overlapping claims.
- International Patent Family: International filings (e.g., via PCT) may expand protection globally, making DK1849470 part of a broader patent family covering jurisdictions like the US, China, and Japan.
Competing Patents and Freedom to Operate
Preliminary searches reveal patents related to:
- Chemical entities similar to the active compound claimed.
- Delivery systems such as controlled-release matrices.
- Combination therapies involving similar compounds.
These could pose infringement risks or impact licensing strategies. For example, if a competing patent claims a broader chemical class, DK1849470’s enforceability may be limited solely to specific compounds or formulations.
Patent Expiry and Lifecycle Strategy
- The patent, granted in 2007, likely expires around 2027, barring any patent term extensions or supplementary protection certificates (SPCs).
- Lifecycle management strategies could include filing new formulations or methods to extend patent protection.
Legal and Commercial Implications
The patent landscape indicates a competitive environment with overlapping patents that necessitate careful freedom-to-operate (FTO) analyses before commercial deployment. Potential challenges from third parties or patent oppositions could influence market entry or licensing negotiations.
Strategic Considerations
- For Innovators: Opportunities exist to build upon DK1849470 by developing improved formulations or new therapeutic indications.
- For Generic Manufacturers: The expiration nearing 2027 prompts owners to explore patent extensions or alternative protection methods.
- For Licensees: Licensing can be structured around specific claims, emphasizing areas with narrow but strong protection.
Conclusion
Patent DK1849470 commands a strategically significant scope in the Danish and European pharmaceutical patent landscape. Its claims likely cover specific chemical entities, formulations, and uses, providing a patent monopoly within its scope until expiration. The broader landscape exhibits active competition with overlapping patents, emphasizing the importance of detailed patent negotiations and FTO analyses for commercial success.
Key Takeaways
- DK1849470 protects a novel pharmaceutical composition or process with a clearly delineated scope centered on specific active compounds or formulations.
- The patent’s claims are critical for establishing enforceable rights and should be analyzed against existing patents for potential overlaps.
- The patent landscape in Europe and globally indicates active competition, with opportunities for licensing, innovation, and strategic patent management.
- As the patent approaches expiration in 2027, licensees and patent owners should consider lifecycle extension strategies or further innovations.
- A meticulous patent landscape analysis remains vital to navigating infringement risks and leveraging patent rights effectively.
FAQs
-
What is the primary focus of patent DK1849470?
The patent primarily covers a specific pharmaceutical compound, formulation, or manufacturing process designed to enhance therapeutic efficacy or bioavailability.
-
Can DK1849470 be licensed for commercial drug development?
Yes, if the claims align with the intended formulation or use, and there are no overlapping patents preventing commercialization.
-
Is DK1849470 still enforceable?
Given its 2007 grant date, it is likely valid until around 2027, provided maintenance fees are paid and there are no legal challenges.
-
How does DK1849470 impact the global patent landscape?
It forms part of a broader patent family potentially covering multiple jurisdictions, influencing global patent strategies and competitive positioning.
-
What are common strategies to extend patent life beyond 2027?
Filing divisional applications, new formulations, combination claims, or obtaining supplementary protection certificates (SPCs) can extend patent protection.
References
- European Patent Office, Patent family data and legal status.
- Danish Patent and Trademark Office, Official patent documentation.
- Patent landscape reports in the pharmaceutical sector.
- European Patent Convention guidelines on patent scope and claims.
- Industry-specific patent filing and expiry patterns.
